Details of Drug | MecDDI

Drug General Information (ID: D1240)
Drug Name		Pembrolizumab
Drug Type		Monoclonal antibody
Disease Class		2A00-2F9Z: Solid tumour/cancer; 2C12: Liver cancer; 2C73: Ovarian cancer; 2A81: Diffuse large B-cell lymphoma; 2C82: Prostate cancer; 2C90: Renal cell carcinoma; 2C25: Lung cancer; 2C60-2C6Y: Breast cancer; 2B91: Colorectal cancer; 2C30: Melanoma; 2B70: Esophageal cancer
Therapeutic Class		Antineoplastics/Anti-Pd-1 Monoclonal Antibodies
External Link
External Link		TTD ID		D08ANZ

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM006 Pharmacodynamic additive effects BM043 Additive immunosuppressive effects BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Pembrolizumab
Pharmacodynamic additive effects
					Additive immunosuppressive effects																																																																Drug Num: 9
Drug ID															Drug Name															Formula															Pubchem ID															Severity Level															Interaction Detail													REF
D0172															Betamethasone															C22H29FO5															9782															Moderate															Inter Info													[4], [5], [6], [7], [8], [9], [10], [11], [12], [13]
D0215															Budesonide															C25H34O6															5281004															Moderate															Inter Info													[4], [5], [6], [7], [8], [9], [10], [11], [12], [13]
D0453															Dexamethasone															C22H29FO5															5743															Moderate															Inter Info													[4], [5], [6], [7], [8], [9], [10], [11], [12], [13]
D0773															Hydrocortisone															C21H30O5															5754															Moderate															Inter Info													[4], [5], [6], [7], [8], [9], [10], [11], [12], [13]
D1041															Methylprednisolone															C22H30O5															6741															Moderate															Inter Info													[4], [5], [6], [7], [8], [9], [10], [11], [12], [13]
D0436															Deflazacort															C25H31NO6															189821															Moderate															Inter Info													[4], [5], [6], [7], [8], [9], [10], [11], [12], [13]
D1332															Prednisolone															C21H28O5															5755															Moderate															Inter Info													[4], [5], [6], [7], [8], [9], [10], [11], [12], [13]
D1334															Prednisone															C21H26O5															5865															Moderate															Inter Info													[4], [5], [6], [7], [8], [9], [10], [11], [12], [13]
D1628															Triamcinolone															C21H27FO6															31307															Moderate															Inter Info													[4], [5], [6], [7], [8], [9], [10], [11], [12], [13]
					Increased risk of other adverse reactions (Unspecific)																																																																Drug Num: 3
Drug ID															Drug Name															Formula															Pubchem ID															Severity Level															Interaction Detail													REF
D0902															Lenalidomide															C13H13N3O3															216326															Major															Inter Info													[1], [2], [3]
D1312															Pomalidomide															C13H11N3O4															134780															Major															Inter Info													[1], [2], [3]
D1569															Thalidomide															C13H10N2O4															5426															Major															Inter Info													[1], [2], [3]

References
1	Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
2	Product Information. Keytruda (pembrolizumab). Merck &amp Company Inc, Whitehouse Station, NJ.
3	Product Information. Revlimid (lenalidomide). Celgene Corporation, Summit, NJ.
4	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
5	Arbour KC, Mezquita L, Long N, et al. "Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer." J Clin Oncol 36 (2018): 2872-2878. [PMID: 30125216]
6	Cerner Multum, Inc "ANVISA Bulario Eletrnico.".
7	Cerner Multum, Inc. "Australian Product Information.".
8	Cerner Multum, Inc. "Canadian Product Information.".
9	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10	Jove M, Vilarino N, Nadal E "Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer." Transl Lung Cancer Res 8 (2019): S364-8. [PMID: 32038916]
11	Scott SC, Pennell NA "Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab." J Thorac Oncol 13 (2018): 1771-5. [PMID: 29935305]
12	Fuca G, Galli G, Poggi M, et.al "Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors." ESMO Open 4 (2019): e000457. [PMID: 30964126]
13	Horvat TZ, Adel NG, Dand TO, et.al "Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center." J Clin Oncol 33 (2015): 3193-8. [PMID: 26282644]